NCT07035093

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 586 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.

Conditions

• Obesity
• Overweight
• Chronic Low Back Pain (CLBP)

Interventions

Type	Name	Description
DRUG	Retatrutide	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2025-05-29
• Primary completion: 2027-09-01
• Completion: 2027-09-01
• First posted: 2025-06-24
• Last updated: 2026-04-17

Locations

41 sites across 5 countries: United States, Argentina, Canada, Mexico, Poland

Regulatory

• FDA-regulated drug study